GMMMG Consultations

On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below.

Title

Information

Feedback

End date

32

Apomorphine use in Parkinson’s Disease

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for Apomorphine use in Parkinson’s Disease is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 20th August 2018.

Feedback Form

5pm Monday
20th August 2018

31

Azathioprine for Interstitial Lung Disease

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for Azathioprine for Interstitial Lung Disease is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm Thursday 9th August 2018.

Feedback Form

5pm Thursday
9th August 2018

30

Oral Methotrexate for IBD

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for Oral Methotrexate for IBD is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 6th August 2018.

Feedback Form

5pm Monday
6th August 2018

29

Goserelin in Breast Cancer

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for Goserelin in Breast Cancer is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm Monday 6th August 2018.

Feedback Form

5pm Monday
6th August 2018

28

FMESG - proposed actions for consultation
[Link removed - consultation closed]

The following actions [Link removed - consultation closed] were proposed at the May 2018 FMESG meeting and are now open for GM wide consultation. Comments [Link removed - consultation closed] are invited up until 5pm Monday 16th July 2018

Feedback Form
[Link removed - consultation closed]

5pm Monday
16th July 2018

27

GM asthma management plan 2018

The GM asthma working group have updated the GM asthma management plan following publication of NICE’s asthma guideline NG80.

The main updates to the GM asthma management plan are as follows:

• Updated to reflect the addition of leukotriene receptor antagonist (montelukast – the only one now) with guidance on deciding between LTRA or LABA/ICS
• The GM plan differs from NICE in that the use of a SABA alone is not included but reflects BTS in that the first step is use of a low dose ICS. It was felt that going back to a SABA-alone option was a retrograde step (ref NRAD report: Overuse of short-acting bronchodilators is a key indicator of poor asthma control and of higher risk of exacerbation and death.)
• As previously, the GM plan includes a smaller number of devices where we have aimed for device consistency throughout which should improve familiarity and ease of use of products for patients and prescribers.
• DuoResp has been replaced by Easyhaler throughout (more economical, provides device consistency)

Please submit any comments using the feedback form. This consultation will close at 5pm on Friday 27th July 2018.

Feedback Form

5pm Friday
27th July 2018